Concurrently, type 2 immunity (IL10 and IL4) has been linked to progression to NASH, and the elevation of plasma IL4, IL5, and IL13 is reported in patients with NASH (55). The gene discussed is IL5; the disease is metabolic dysfunction-associated steatohepatitis.